Tus Pharmaceutical Group Co Ltd
SZSE:000590
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
T
|
Tus Pharmaceutical Group Co Ltd
SZSE:000590
|
CN |
Balance Sheet
Balance Sheet Decomposition
Tus Pharmaceutical Group Co Ltd
Tus Pharmaceutical Group Co Ltd
Balance Sheet
Tus Pharmaceutical Group Co Ltd
| Dec-2002 | Dec-2003 | Dec-2004 | Dec-2005 | Dec-2006 | Dec-2007 | Dec-2008 | Dec-2009 | Dec-2010 | Dec-2011 | Dec-2012 | Dec-2013 | Dec-2014 | Dec-2015 | Dec-2016 | Dec-2017 | Dec-2018 | Dec-2019 | Dec-2020 | Dec-2021 | Dec-2022 | Dec-2023 | Dec-2024 | Dec-2025 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | |||||||||||||||||||||||||
| Cash & Cash Equivalents |
41
|
11
|
18
|
39
|
23
|
25
|
16
|
14
|
9
|
28
|
159
|
66
|
48
|
56
|
123
|
124
|
321
|
314
|
343
|
246
|
235
|
178
|
161
|
170
|
|
| Cash |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
246
|
235
|
178
|
161
|
170
|
|
| Cash Equivalents |
41
|
11
|
18
|
39
|
23
|
25
|
16
|
14
|
9
|
28
|
159
|
66
|
48
|
56
|
123
|
124
|
321
|
314
|
343
|
0
|
0
|
0
|
0
|
0
|
|
| Short-Term Investments |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
193
|
0
|
0
|
0
|
75
|
25
|
0
|
0
|
0
|
|
| Total Receivables |
195
|
220
|
239
|
226
|
297
|
205
|
175
|
119
|
130
|
105
|
151
|
107
|
143
|
112
|
94
|
140
|
66
|
126
|
113
|
131
|
147
|
215
|
194
|
87
|
|
| Accounts Receivables |
166
|
182
|
187
|
183
|
250
|
122
|
112
|
63
|
43
|
37
|
30
|
28
|
11
|
12
|
4
|
16
|
17
|
6
|
2
|
0
|
24
|
22
|
8
|
2
|
|
| Other Receivables |
29
|
39
|
52
|
42
|
47
|
82
|
63
|
57
|
87
|
68
|
122
|
80
|
133
|
100
|
90
|
125
|
50
|
120
|
111
|
131
|
123
|
193
|
186
|
85
|
|
| Inventory |
121
|
110
|
92
|
83
|
37
|
55
|
77
|
63
|
86
|
88
|
70
|
64
|
42
|
69
|
67
|
63
|
69
|
51
|
51
|
87
|
118
|
130
|
125
|
110
|
|
| Other Current Assets |
13
|
10
|
10
|
10
|
7
|
13
|
7
|
8
|
11
|
9
|
10
|
43
|
22
|
1
|
1
|
1
|
30
|
1
|
2
|
15
|
4
|
16
|
21
|
12
|
|
| Total Current Assets |
371
|
351
|
358
|
357
|
363
|
297
|
275
|
204
|
235
|
229
|
391
|
280
|
255
|
239
|
284
|
522
|
487
|
492
|
509
|
554
|
529
|
540
|
500
|
379
|
|
| PP&E Net |
254
|
219
|
212
|
215
|
130
|
128
|
130
|
135
|
154
|
178
|
179
|
122
|
170
|
154
|
159
|
165
|
171
|
201
|
225
|
241
|
290
|
294
|
313
|
312
|
|
| PP&E Gross |
254
|
219
|
212
|
215
|
130
|
128
|
130
|
135
|
154
|
178
|
179
|
122
|
170
|
154
|
159
|
165
|
171
|
201
|
225
|
241
|
290
|
294
|
313
|
312
|
|
| Accumulated Depreciation |
107
|
119
|
134
|
148
|
102
|
92
|
97
|
96
|
104
|
114
|
126
|
179
|
102
|
112
|
119
|
122
|
138
|
147
|
159
|
170
|
193
|
209
|
219
|
239
|
|
| Intangible Assets |
92
|
76
|
67
|
57
|
16
|
85
|
142
|
139
|
137
|
134
|
132
|
146
|
156
|
191
|
172
|
168
|
138
|
135
|
138
|
134
|
157
|
132
|
131
|
123
|
|
| Goodwill |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
7
|
0
|
0
|
0
|
0
|
0
|
137
|
132
|
13
|
0
|
|
| Note Receivable |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
7
|
5
|
3
|
2
|
|
| Long-Term Investments |
6
|
37
|
38
|
35
|
42
|
30
|
30
|
35
|
41
|
60
|
3
|
3
|
1
|
0
|
0
|
15
|
15
|
15
|
14
|
32
|
36
|
40
|
38
|
51
|
|
| Other Long-Term Assets |
2
|
1
|
1
|
1
|
11
|
8
|
9
|
3
|
2
|
1
|
1
|
1
|
5
|
4
|
8
|
4
|
6
|
5
|
6
|
7
|
10
|
9
|
16
|
22
|
|
| Other Assets |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
7
|
0
|
0
|
0
|
0
|
0
|
137
|
132
|
13
|
0
|
|
| Total Assets |
725
N/A
|
685
-5%
|
677
-1%
|
665
-2%
|
562
-15%
|
549
-2%
|
586
+7%
|
516
-12%
|
569
+10%
|
603
+6%
|
704
+17%
|
553
-22%
|
587
+6%
|
587
+0%
|
631
+7%
|
874
+39%
|
817
-7%
|
847
+4%
|
892
+5%
|
968
+8%
|
1 167
+21%
|
1 151
-1%
|
1 013
-12%
|
889
-12%
|
|
| Liabilities | |||||||||||||||||||||||||
| Accounts Payable |
91
|
79
|
78
|
64
|
48
|
47
|
62
|
68
|
78
|
73
|
83
|
86
|
46
|
42
|
42
|
44
|
27
|
35
|
32
|
32
|
50
|
84
|
73
|
64
|
|
| Accrued Liabilities |
52
|
35
|
37
|
44
|
34
|
24
|
52
|
53
|
60
|
50
|
11
|
18
|
32
|
33
|
26
|
33
|
23
|
31
|
35
|
46
|
51
|
47
|
48
|
42
|
|
| Short-Term Debt |
251
|
261
|
239
|
232
|
160
|
124
|
106
|
101
|
58
|
63
|
0
|
0
|
78
|
64
|
113
|
38
|
52
|
36
|
47
|
42
|
66
|
32
|
36
|
28
|
|
| Current Portion of Long-Term Debt |
0
|
0
|
4
|
0
|
0
|
0
|
0
|
4
|
10
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
3
|
13
|
12
|
14
|
21
|
|
| Other Current Liabilities |
29
|
31
|
36
|
39
|
26
|
39
|
34
|
47
|
81
|
63
|
122
|
140
|
162
|
127
|
74
|
49
|
40
|
52
|
48
|
65
|
92
|
75
|
65
|
46
|
|
| Total Current Liabilities |
422
|
406
|
394
|
381
|
267
|
234
|
253
|
273
|
287
|
249
|
216
|
244
|
318
|
265
|
255
|
165
|
141
|
154
|
161
|
187
|
271
|
249
|
236
|
201
|
|
| Long-Term Debt |
22
|
20
|
16
|
16
|
0
|
0
|
14
|
10
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
20
|
20
|
0
|
0
|
6
|
95
|
83
|
84
|
51
|
|
| Deferred Income Tax |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
7
|
6
|
5
|
6
|
|
| Minority Interest |
3
|
1
|
0
|
1
|
0
|
0
|
0
|
1
|
0
|
0
|
0
|
0
|
0
|
0
|
3
|
0
|
0
|
0
|
0
|
2
|
4
|
4
|
3
|
2
|
|
| Other Liabilities |
0
|
0
|
0
|
0
|
8
|
8
|
0
|
3
|
3
|
3
|
10
|
39
|
84
|
117
|
112
|
106
|
76
|
71
|
86
|
93
|
90
|
85
|
87
|
82
|
|
| Total Liabilities |
441
N/A
|
427
-3%
|
409
-4%
|
395
-3%
|
275
-30%
|
241
-12%
|
267
+11%
|
285
+6%
|
290
+2%
|
252
-13%
|
225
-10%
|
283
+26%
|
403
+42%
|
382
-5%
|
370
-3%
|
290
-21%
|
237
-18%
|
225
-5%
|
247
+10%
|
288
+16%
|
469
+63%
|
427
-9%
|
415
-3%
|
342
-18%
|
|
| Equity | |||||||||||||||||||||||||
| Common Stock |
203
|
203
|
203
|
203
|
203
|
203
|
203
|
203
|
203
|
203
|
223
|
223
|
223
|
223
|
223
|
240
|
240
|
240
|
240
|
239
|
239
|
239
|
239
|
239
|
|
| Retained Earnings |
32
|
59
|
53
|
49
|
36
|
15
|
1
|
86
|
39
|
33
|
103
|
107
|
192
|
170
|
115
|
96
|
134
|
91
|
69
|
33
|
15
|
10
|
115
|
166
|
|
| Additional Paid In Capital |
121
|
121
|
118
|
118
|
120
|
119
|
115
|
115
|
115
|
115
|
153
|
152
|
152
|
152
|
152
|
440
|
474
|
474
|
474
|
474
|
474
|
474
|
474
|
474
|
|
| Unrealized Security Profit/Loss |
9
|
7
|
1
|
3
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Equity |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Equity |
283
N/A
|
259
-9%
|
268
+3%
|
269
+1%
|
287
+7%
|
307
+7%
|
319
+4%
|
232
-27%
|
279
+20%
|
351
+26%
|
479
+36%
|
270
-44%
|
184
-32%
|
206
+12%
|
261
+27%
|
583
+123%
|
580
-1%
|
622
+7%
|
645
+4%
|
680
+5%
|
698
+3%
|
724
+4%
|
598
-17%
|
548
-8%
|
|
| Total Liabilities & Equity |
725
N/A
|
685
-5%
|
677
-1%
|
665
-2%
|
562
-15%
|
549
-2%
|
586
+7%
|
516
-12%
|
569
+10%
|
603
+6%
|
704
+17%
|
553
-22%
|
587
+6%
|
587
+0%
|
631
+7%
|
874
+39%
|
817
-7%
|
847
+4%
|
892
+5%
|
968
+8%
|
1 167
+21%
|
1 151
-1%
|
1 013
-12%
|
889
-12%
|
|
| Shares Outstanding | |||||||||||||||||||||||||
| Common Shares Outstanding |
223
|
223
|
223
|
223
|
223
|
223
|
223
|
223
|
223
|
223
|
223
|
223
|
223
|
223
|
223
|
240
|
240
|
240
|
240
|
239
|
239
|
239
|
239
|
239
|
|